The Diagenode agreement is the first in what BD expects to be a string of similar deals with molecular diagnostics developers in order to expand the number of tests that can run on the BD Max.
The partnership combines Seegene's Dual Priming Oligo multiplex PCR technology with Akonni's TruArray gel-drop microarray technology.
The companies will co-develop seven assays for pathogens associated with respiratory, enteric, and central nervous system diseases.
The firms will combine their technologies to develop molecular diagnostic tests for infectious pathogens that cause respiratory diseases.
Celera will manufacture the multiplex assay, which will be the next-generation version of Qiagen's ResPlex II assay for detecting respiratory pathogens.
The company will use an SBIR and an STTR grant to develop POC tests for HIV and respiratory diseases.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.